Abstract
Low-grade gliomas (LGG) are the most frequent pediatric tumors
associated with epilepsy. Molecular sequencing analyses have defined the
genomic landscape of these tumors leading to the use of targeted
therapies, which have proven to be efficacious. Ongoing clinical trials
are testing the incorporation of these drugs, especially in unresectable
LGG that progress after standard treatment. Nevertheless, this strategy
is not extended in the field of tumor-induced epilepsy. We present a
patient with drug-resistant epilepsy secondary to a BRAF V600E-mutated
ganglioglioma treated with dabrafenib who showed a dramatic radiological
and clinical response with marked improvement in her quality of life.